PRESS RELEASE published on 04/04/2025 at 14:00, 1 year 5 months ago Postponement Annual Shareholders Meeting Oxurion NV postponed its Annual Shareholders Meeting to May 13, 2025, due to pending annual accounts. The biopharmaceutical company, focused on ophthalmic therapies, is based in Leuven, Belgium Biopharmaceutical Annual Shareholders Meeting Postponed Ophthalmic Therapies Oxurion NV
BRIEF published on 04/02/2025 at 18:05, 1 year 5 months ago Oxurion Receives Transparency Notification from Atlas Special Opportunities II LLC Actions Transparency Atlas Special Opportunities Oxurion Biopharmacy
PRESS RELEASE published on 04/02/2025 at 18:00, 1 year 5 months ago Oxurion Receives Transparency Notification from Atlas Special Opportunities II LLC Oxurion NV, a biopharmaceutical company, received a transparency notification from Atlas Special Opportunities II, LLC regarding shareholding threshold crossing under Belgian legislation Transparency Notification Shareholding Threshold Oxurion NV Belgian Legislation Atlas Special Opportunities II LLC
BRIEF published on 03/27/2025 at 18:05, 1 year 5 months ago Oxurion receives adjusted transparency notification Transparency Notification Shareholding Oxurion Atlas Special Opportunities II Brussels Stock Exchange
PRESS RELEASE published on 03/27/2025 at 18:00, 1 year 5 months ago Oxurion Receives Amended Transparency Notification from Atlas Special Opportunities II LLC Oxurion NV received an amended transparency notification from Atlas Special Opportunities II, LLC regarding the sale of voting securities. This press release replaces the one from March 18, 2025 Transparency Notification Euronext Brussels Oxurion NV Retinal Disease Therapies Atlas Special Opportunities II
BRIEF published on 03/24/2025 at 18:05, 1 year 5 months ago Oxurion Announces Capital Increase Following Convertible Bond Conversion Convertible Bonds Capital Increase Atlas Special Opportunities Ophthalmic Therapies Oxurion
PRESS RELEASE published on 03/24/2025 at 18:00, 1 year 5 months ago Information on the Total Number of Voting Rights (Denominator) following Conversion Notice from Atlas Atlas Special Opportunities, LLC converts bonds in Oxurion, resulting in EUR 150,000 capital increase. Oxurion focuses on developing therapeutics for vision care Capital Increase Therapeutics Vision Care Atlas Special Opportunities LLC Oxurion
BRIEF published on 03/18/2025 at 18:35, 1 year 5 months ago Oxurion Signs Letter of Intent for Acquisition of Biometrics-Focused CRO Regulatory Compliance Oxurion Acquisition Biometrics CRO Clinical Data Management ECRF Platform
PRESS RELEASE published on 03/18/2025 at 18:30, 1 year 5 months ago Oxurion signs a letter of intent for the planned acquisition of a biometrics-focused CRO Oxurion NV plans to acquire majority stake in a specialized CRO for clinical data management. Strategic move aligns with company's expansion strategy. Transaction valued at €650,000 Acquisition CRO Biometric Analysis Oxurion NV Clinical Data Management
BRIEF published on 03/18/2025 at 18:05, 1 year 5 months ago Oxurion Announces Transparency Updates Regarding Atlas Special Opportunities Atlas Special Opportunities Oxurion Belgian Legislation Transparency Notifications Voting Securities
Published on 09/16/2026 at 16:55, 3 hours 59 minutes ago CORRECTION FROM SOURCE: SLAM Reports 1.60% Copper Equivalent Over 14.45 Meters in Hole GW26-33; Trenching Gold-Antimony Targets on Moose Lake Project
Published on 09/16/2026 at 15:00, 5 hours 54 minutes ago 2026 Canada's Top 40 Under 40(R) Honourees Announced
Published on 09/16/2026 at 14:00, 6 hours 54 minutes ago Ameriwest Awaits Bornite Core Assay Results and Provides Q3 2026 Corporate Update
Published on 09/16/2026 at 13:30, 7 hours 24 minutes ago Sterling Extends Core MEPS Copper Zone to 700m; Intersects 200m of 0.53% CuEq Including 102m of 0.81% CuEq
Published on 09/16/2026 at 13:23, 7 hours 31 minutes ago SLAM Reports 1.60% Copper Equivalent Over 14.45 Meters in Hole GW26-33; Trenching Gold-Antimony Targets on Moose Lake Project
Published on 09/16/2026 at 20:27, 26 minutes ago EQS-Adhoc: REPLOID Group AG resolves to issue convertible notes in an aggregate principal amount of up to EUR 30 million
Published on 09/16/2026 at 19:05, 1 hour 48 minutes ago EcoFlow to showcase its open home energy ecosystem at Solar & Storage Live Zurich 2026
Published on 09/16/2026 at 18:22, 2 hours 32 minutes ago EQS-Adhoc: elumeo SE resolves on a capital increase against cash contributions, ex-cluding pre-emptive rights, and a move to the Scale segment
Published on 09/16/2026 at 18:11, 2 hours 42 minutes ago EQS-Adhoc: Berentzen-Gruppe Aktiengesellschaft confirms rumours regarding negotiations on a voluntary takeover offer by SAZERAC COMPANY, INC.
Published on 09/16/2026 at 18:05, 2 hours 48 minutes ago LawZero receives a commitment of up to $300M in joint funding from Canada and Germany
Published on 09/16/2026 at 17:45, 3 hours 9 minutes ago Report on share repurchases from 9 to 15 September 2026
Published on 09/16/2026 at 07:00, 13 hours 54 minutes ago bioMérieux Receives IVDR Class D CE Marking for BIOFIRE® Respiratory 2.1 plus Panel and BIOFIRE® FILMARRAY® Pneumonia plus Panel, the first syndromic tests including MERS-CoV to achieve this certification
Published on 09/15/2026 at 18:00, 1 day 2 hours ago Report on the Combined General Meeting of the 10th of September 2026
